Company news

BeyondSpring, Inc. news in 2026

BeyondSpring, Inc.'s news releases, calls and decks from 2026, newest first.

View company

FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in…

September 29, 2026

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

September 29, 2026

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

August 14, 2026

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

June 3, 2026

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

June 2, 2026

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

May 18, 2026

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

April 22, 2026

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

March 29, 2026

BeyondSpring Reports 2025 Year-End Financial Results

March 24, 2026

BeyondSpring Files 2025 Annual Report on Form 10-K

March 24, 2026

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

February 9, 2026

Decks in 2026